Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IVAX Insider Trading -- Ignore unavailable to you. Want to Upgrade?

To: flickerful who wrote (389)	1/4/1998 2:40:00 PM
From: 5,17,37,5,101,...	Read Replies (2) \| Respond to of 756

Every single thing points to a bottom in Ivax; hold on. There are even a bunch of nickle-and-dime shorts on the Yahoo! thread trying to babble the stock lower. As for the consolidation in the industry, Ivax will be gobbled first. Frost knows that he's been beaten. He's not one to be attached to his holdings. A buyer will eliminate all general and administrative expenses, essentially doubling cash flow; and then will have a nice outlet for its drugs going off patent. That means a hefty premium to today's market price, maybe $15.00 to $17.50 per share. Look to late May or early June for an announcement. Between now and then, Frost will work the stock higher to the $10.00 area so he can get that higher premium. A bevy of FDA approvals here, a corporate development there, a few well-timed subtle susurrations, people begin to put two and two together and before you know it we are at $10.00 and ready for our news. Yours from Dreamsville, Jackson